Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure-Reference-Cited by-同舟云学术

Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure

Published:2021-07-30 Issue:4 Volume:2 Page:541-544
ISSN:2628-491X
Container-title:Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
language:en
Short-container-title:

Author:

Gruson Damien¹²,Adamantidou Christina³,Ahn Sylvie A.³,Rousseau Michel F.³

Affiliation:

1. Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique , Cliniques Universitaires St-Luc and Université Catholique de Louvain , Brussels , Belgium

2. Department of Clinical Biochemistry , Cliniques Universitaires St-Luc and Université Catholique de Louvain , Brussels , Belgium

3. Division of Cardiology, Cliniques Universitaires St-Luc and Pôle de recherche cardiovasculaire , Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain , Brussels , Belgium

Abstract

Abstract Objectives To determine concentrations of heart-type fatty acid-binding protein (HFABP) in patients with heart failure with reduced ejection fraction (HFrEF) and its potential value for prognostic assessment. Methods Circulating levels of HFABP were measured with an automated chemiluminescent immunoassay in 25 healthy volunteers and 60 HFrEF patients. Results Concentrations of HFABP were significantly increased in heart failure patients in comparison to healthy volunteers. HFABP levels were significantly correlated to New York Heart Association classes and to established biomarkers of cardiac dysfunction and remodeling (amino-terminal pro-B-type natriuretic peptide [NT-proBNP], fibroblast growth factor 23, and galectin-3). HFABP concentrations were also predictive of cardiovascular (CV) death and combination with NT-proBNP might be synergistic for risk assessment. Conclusions HFABP levels are increased in HFrEF patients, related to adverse CV outcomes, and might assist physicians for patient’s management.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/almed-2021-0035/pdf

Reference15 articles.

1. Seferovic, PM, Ponikowski, P, Anker, SD, Bauersachs, J, Chioncel, O, Cleland, JGF, et al.. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. [Internet]. Eur J Heart Fail 2019;21:1169–86.

2. Groenewegen, A, Rutten, FH, Mosterd, A, Hoes, AW. Epidemiology of heart failure. [Internet]. Eur J Heart Fail 2020;22:1342–56.

3. Mueller, C, McDonald, K, de Boer, RA, Maisel, A, Cleland, JGF, Kozhuharov, N, et al.. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. [Internet]. Eur J Heart Fail 2019;21:715–31.

4. Ponikowski, P, Voors, AA, Anker, SD, Bueno, H, Cleland, JGF, Coats, AJS, et al.. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. [Internet]. Eur Heart J 2016;37:2129–200.

5. Burns, DJP, Arora, J, Okunade, O, Beltrame, JF, Bernardez-Pereira, S, Crespo-Leiro, MG, et al.. International Consortium for health outcomes measurement (ICHOM): standardized patient-centered outcomes measurement set for heart failure patients. [Internet]. JACC Hear Fail 2020;8:212–22.